Lexicon Pharmaceuticals (LXRX) EBITDA (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of EBITDA data on file, last reported at -$996000.0 in Q1 2026.

• On a quarterly basis, EBITDA rose 96.12% year-over-year to -$996000.0 in Q1 2026; TTM through Mar 2026 was -$24.2 million, a 86.35% increase from a year earlier, with the FY2025 full-year figure at -$48.9 million, up 75.19% from the prior year.
• EBITDA for Q1 2026 stood at -$996000.0, up from -$14.8 million in the prior quarter.
• Over the last five years, EBITDA for LXRX reached as high as $3.7 million in Q2 2025 and fell as low as -$63.7 million in Q3 2024.
• Historically, EBITDA has averaged -$30.6 million across 5 years, with a median of -$30.3 million in 2022.
• Across the five-year window, EBITDA sank 114.9% in 2023 and soared 106.75% in 2025, its largest moves.
• Year by year, EBITDA stood at -$30.3 million in 2022, then sank by 54.36% to -$46.7 million in 2023, then grew by 29.95% to -$32.7 million in 2024, then jumped by 54.85% to -$14.8 million in 2025, then jumped by 93.26% to -$996000.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$996000.0 in Q1 2026, -$14.8 million in Q4 2025, and -$12.2 million in Q3 2025.